Article Excerpt: The Digital Therapeutics Alliance will soon launch an accreditation program for digital therapeutics products through DirectTrust, which contracts with a slew of payers. Payers, especially the Centers for Medicare and Medicaid Services (CMS), have been hesitant to cover the products because of key DTx companies that announced bankruptcy last year, like Pear Therapeutics.
Andy Molnar, CEO of the Digital Therapeutics Alliance, announced this morning at the organization’s annual conference that it will begin to accredit digital therapeutics products to help build confidence in the industry. Through the collaborative partnership, DTA will establish criteria for evaluating efficacy of digital therapeutics products and DirectTrust will utilize existing standards for privacy, security and interoperability of the devices.
Full Article: https://tinyurl.com/y8282927
Article Source: FIERCE Healthcare